Literature DB >> 28090432

Update on Chronic Lung Allograft Dysfunction.

Jason M Gauthier1, Ramsey R Hachem2, Daniel Kreisel3.   

Abstract

Chronic lung allograft dysfunction (CLAD) encompasses a range of pathologies that cause a transplanted lung to not achieve or maintain normal function. CLAD manifests as airflow restriction and/or obstruction and is predominantly a result of chronic rejection. Three distinct phenotypes of chronic rejection are now recognized: bronchiolitis obliterans, neutrophilic reversible allograft dysfunction, and restrictive allograft syndrome. Recent investigations have revealed that each phenotype has a unique pathology and histopathological findings, suggesting that treatment regimens should be tailored to the underlying etiology. CLAD is poorly responsive to treatment once diagnosed, and therefore the prevention of the factors that predispose a patient to develop CLAD is critically important. Small and large animal models have contributed significantly to our understanding of CLAD and more studies are needed to develop treatment regimens that are effective in humans.

Entities:  

Keywords:  azithromycin responsive allograft dysfunction; bronchiolitis obliterans; bronchiolitis obliterans syndrome; chronic lung allograft dysfunction; neutrophilic reversible allograft dysfunction; restrictive allograft syndrome

Year:  2016        PMID: 28090432      PMCID: PMC5233406          DOI: 10.1007/s40472-016-0112-y

Source DB:  PubMed          Journal:  Curr Transplant Rep


  62 in total

1.  Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation.

Authors:  T J Kroshus; V R Kshettry; K Savik; R John; M I Hertz; R M Bolman
Journal:  J Thorac Cardiovasc Surg       Date:  1997-08       Impact factor: 5.209

2.  The safety and efficacy of total lymphoid irradiation in progressive bronchiolitis obliterans syndrome after lung transplantation.

Authors:  Andrew J Fisher; Robert M Rutherford; Joseph Bozzino; Gareth Parry; John H Dark; Paul A Corris
Journal:  Am J Transplant       Date:  2005-03       Impact factor: 8.086

3.  A relevant experimental model for human bronchiolitis obliterans syndrome.

Authors:  Srebrena Atanasova; Markus Hirschburger; Danny Jonigk; Martin Obert; Kathrin Petri; Alena Evers; Andreas Hecker; Jessica Schmitz; Andreas Kaufmann; Jochen Wilhelm; Trinad Chakraborty; Gregor Warnecke; Jens Gottlieb; Winfried Padberg; Veronika Grau
Journal:  J Heart Lung Transplant       Date:  2013-09-16       Impact factor: 10.247

4.  Survival After Lung Retransplantation in the United States in the Current Era (2004 to 2013): Better or Worse?

Authors:  Mathew Thomas; Erol V Belli; Bhupendra Rawal; Richard C Agnew; Kevin P Landolfo
Journal:  Ann Thorac Surg       Date:  2015-07-02       Impact factor: 4.330

5.  Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway.

Authors:  Hanzhong Liu; Peter Drew; Andrew C Gaugler; Yanping Cheng; Gary A Visner
Journal:  Am J Transplant       Date:  2005-06       Impact factor: 8.086

6.  Lung transplant acceptance is facilitated by early events in the graft and is associated with lymphoid neogenesis.

Authors:  W Li; A C Bribriesco; R G Nava; A A Brescia; A Ibricevic; J H Spahn; S L Brody; J H Ritter; A E Gelman; A S Krupnick; M J Miller; D Kreisel
Journal:  Mucosal Immunol       Date:  2012-05-02       Impact factor: 7.313

7.  Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study.

Authors:  Geert M Verleden; Stijn E Verleden; Robin Vos; Stéphanie I De Vleeschauwer; Lieven J Dupont; Dirk E Van Raemdonck; Bart M Vanaudenaerde
Journal:  Transpl Int       Date:  2011-03-14       Impact factor: 3.782

8.  Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation.

Authors:  L Fan; H L Benson; R Vittal; E A Mickler; R Presson; A Jo Fisher; O W Cummings; K M Heidler; M R Keller; W J Burlingham; D S Wilkes
Journal:  Am J Transplant       Date:  2011-04-19       Impact factor: 8.086

Review 9.  A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy.

Authors:  B M Vanaudenaerde; I Meyts; R Vos; N Geudens; W De Wever; E K Verbeken; D E Van Raemdonck; L J Dupont; G M Verleden
Journal:  Eur Respir J       Date:  2008-10       Impact factor: 16.671

10.  Pirfenidone: a potential new therapy for restrictive allograft syndrome?

Authors:  R Vos; S E Verleden; D Ruttens; E Vandermeulen; J Yserbyt; L J Dupont; D E Van Raemdonck; N De Raedt; O Gheysens; P A De Jong; G M Verleden; B M Vanaudenaerde
Journal:  Am J Transplant       Date:  2013-09-18       Impact factor: 8.086

View more
  14 in total

Review 1.  Diagnosis, Pathophysiology and Experimental Models of Chronic Lung Allograft Rejection.

Authors:  Jason M Gauthier; Daniel Ruiz-Pérez; Wenjun Li; Ramsey R Hachem; Varun Puri; Andrew E Gelman; Daniel Kreisel
Journal:  Transplantation       Date:  2018-09       Impact factor: 4.939

Review 2.  Mechanisms of graft rejection after lung transplantation.

Authors:  Hsi-Min Hsiao; Davide Scozzi; Jason M Gauthier; Daniel Kreisel
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

3.  Pediatric lung transplantation: Dynamics of the microbiome and bronchiolitis obliterans in cystic fibrosis.

Authors:  Ahmed A Metwally; Christian Ascoli; Benjamin Turturice; Asha Rani; Ravi Ranjan; Yang Chen; Cody Schott; Albert Faro; Thomas W Ferkol; Patricia W Finn; David L Perkins
Journal:  J Heart Lung Transplant       Date:  2020-05-19       Impact factor: 10.247

4.  Prognostic impact of preoperative respiratory colonization on early-onset pneumonia after lung transplantation.

Authors:  Taehwa Kim; Hye Ju Yeo; Jin Ho Jang; Dohyung Kim; Doosoo Jeon; Yun Seong Kim; Woo Hyun Cho
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

5.  A novel model for dissecting roles of IL-17 in lung transplantation.

Authors:  Rongjuan Chen; Fan Liang; Qirui Chen; Jiangnan Xu; Yaozhong Ding
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 6.  Oscillometry of the respiratory system: a translational opportunity not to be missed.

Authors:  Lennart K A Lundblad; Annette Robichaud
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-04-06       Impact factor: 5.464

7.  Clinical Outcomes of Lung Transplants From Donors With Unexpected Pulmonary Embolism.

Authors:  Yuriko Terada; Jason M Gauthier; Michael K Pasque; Tsuyoshi Takahashi; Jingxia Liu; Ruben G Nava; Ramsey R Hachem; Chad A Witt; Derek E Byers; Rodrigo Vazquez Guillamet; Benjamin D Kozower; Bryan F Meyers; Patrick R Aguilar; Hrishikesh S Kulkarni; G Alexander Patterson; Daniel Kreisel; Varun Puri
Journal:  Ann Thorac Surg       Date:  2020-10-22       Impact factor: 5.102

8.  Double lung, unlike single lung transplantation might provide a protective effect on mortality and bronchiolitis obliterans syndrome.

Authors:  Mohammed Fakhro; Ellen Broberg; Lars Algotsson; Lennart Hansson; Bansi Koul; Ronny Gustafsson; Per Wierup; Richard Ingemansson; Sandra Lindstedt
Journal:  J Cardiothorac Surg       Date:  2017-11-25       Impact factor: 1.637

9.  Survival Associated With Sirolimus Plus Tacrolimus Maintenance Without Induction Therapy Compared With Standard Immunosuppression After Lung Transplant.

Authors:  Marniker Wijesinha; Jon Mark Hirshon; Michael Terrin; Laurence Magder; Clayton Brown; Kristen Stafford; Aldo Iacono
Journal:  JAMA Netw Open       Date:  2019-08-02

Review 10.  Infection prophylaxis and management of fungal infections in lung transplant.

Authors:  Armelle Pérez-Cortés Villalobos; Shahid Husain
Journal:  Ann Transl Med       Date:  2020-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.